The NEDD8-activating enzyme (NAE) initiates a protein homeostatic pathway essential for cancer cell growth and survival. MLN4924 is a selective inhibitor of NAE currently in clinical trials for the treatment of cancer. Here, we show that MLN4924 is a mechanism-based inhibitor of NAE and creates a covalent NEDD8-MLN4924 adduct catalyzed by the enzyme. The NEDD8-MLN4924 adduct resembles NEDD8 adenylate, the first intermediate in the NAE reaction cycle, but cannot be further utilized in subsequent intraenzyme reactions. The stability of the NEDD8-MLN4924 adduct within the NAE active site blocks enzyme activity, thereby accounting for the potent inhibition of the NEDD8 pathway by MLN4924. Importantly, we have determined that compounds resembling MLN4924 demonstrate the ability to form analogous adducts with other ubiquitin-like proteins (UBLs) catalyzed by their cognate-activating enzymes. These findings reveal insights into the mechanism of E1s and suggest a general strategy for selective inhibition of UBL conjugation pathways.
Ubiquitin-activating enzyme (UAE or E1) activates ubiquitin via an adenylate intermediate and catalyzes its transfer to a ubiquitin-conjugating enzyme (E2).Mechanistic studies on Compound I and its purified ubiquitin adduct demonstrate that the proposed substrate-assisted inhibition via covalent adduct formation is entirely consistent with the three-step ubiquitin activation process and that the adduct is formed via nucleophilic attack of UAE thioester by the sulfamate group of Compound I after completion of step 2. Kinetic and affinity analysis of Compound I, MLN4924, and their purified ubiquitin adducts suggest that both the rate of adduct formation and the affinity between the adduct and E1 contribute to the overall potency. Because all E1s are thought to use a similar mechanism to activate their cognate ubiquitin-like proteins, the substrate-assisted inhibition by adenosine sulfamate analogues represents a promising strategy to develop potent and selective E1 inhibitors that can modulate diverse biological pathways.Post-translational modification by ubiquitin plays an essential role in a wide range of cellular processes. One of the most intensively studied pathways is the ubiquitin-proteasome system that attaches a polyubiquitin chain to a lysine residue on a target protein and directs it to proteasome-mediated proteolysis. The ubiquitin-proteasome system is a key system responsible for maintaining cellular protein homeostasis, an emerging research area that could potentially transform our understanding of human diseases (1-3). Bortezomib (VELCADE), a proteasome inhibitor, is currently approved in the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma (4, 5). The clinical success of bortezomib suggests that targeting other components in the ubiquitin-proteasome system pathway might represent an opportunity to develop novel anti-cancer therapeutics (6 -9).Conjugating ubiquitin to a protein substrate is mediated by an enzymatic cascade initiated by ubiquitin-activating enzyme (UAE) 2 (or Ube1 in humans, also known as E1) (10). Previous mechanistic studies show that, in vitro, UAE activates ubiquitin by a three-step process using ATP as a cofactor (Fig. 1A) (11,12). In step 1, UAE binds ATP and ubiquitin, catalyzes formation of ubiquitin adenylate intermediate, and releases inorganic pyrophosphate (PP i ). The ubiquitin adenylate activates the C-terminal carboxyl group of ubiquitin for nucleophilic substitution. In step 2, the catalytic cysteine residue in UAE attacks the adenylate to form a thioester intermediate (UAE-Sϳubiq-uitin, ϳ denotes the thioester bond between the C-terminal carboxyl group of ubiquitin and Cys 632 of human UAE) with AMP as the by-product. In step 3, UAE-Sϳubiquitin binds another equivalent of ATP and ubiquitin and in a second round of adenylation, forms a UAE-Sϳubiquitin⅐ubiquitin-adenylate ternary complex. Although UAE-Sϳubiquitin is capable of transferring ubiquitin to the conjugating enzyme (E2) via a transthiolation reaction, E1-E2 transthiolation is grea...
MLN4924 is an investigational small-molecule inhibitor of NEDD8-activating enzyme (NAE) in clinical trials for the treatment of cancer. MLN4924 is a mechanism-based inhibitor, with enzyme inhibition occurring through the formation of a tight-binding NEDD8-MLN4924 adduct. In cell and xenograft models of cancer, we identified treatment-emergent heterozygous mutations in the adenosine triphosphate binding pocket and NEDD8-binding cleft of NAEβ as the primary mechanism of resistance to MLN4924. Biochemical analyses of NAEβ mutants revealed slower rates of adduct formation and reduced adduct affinity for the mutant enzymes. A compound with tighter binding properties was able to potently inhibit mutant enzymes in cells. These data provide rationales for patient selection and the development of next-generation NAE inhibitors designed to overcome treatment-emergent NAEβ mutations.
The effect of [CO] on acetyl-CoA synthesis activity of the isolated alpha subunit of acetyl-coenzyme A synthase/carbon monoxide dehydrogenase from Moorella thermoacetica was determined. In contrast to the complete alpha(2)beta(2) enzyme where multiple CO molecules exhibit strong cooperative inhibition, alpha was weakly inhibited, apparently by a single CO with K(I) = 1.5 +/- 0.5 mM; other parameters include k(cat) = 11 +/- 1 min(-)(1) and K(M) = 30 +/- 10 microM. The alpha subunit lacked the previously described "majority" activity of the complete enzyme but possessed its "residual" activity. The site affording cooperative inhibition may be absent or inoperative in isolated alpha subunits. Ni-activated alpha rapidly and reversibly accepted a methyl group from CH(3)-Co(3+)FeSP affording the equilibrium constant K(MT) = 10 +/- 4, demonstrating the superior nucleophilicity of alpha(red) relative to Co(1+)FeSP. CO inhibited this reaction weakly (K(I) = 540 +/- 190 microM). NiFeC EPR intensity of alpha developed in accordance with an apparent K(d) = 30 microM, suggesting that the state exhibiting this signal is not responsible for inhibiting catalysis or methyl group transfer and that it may be a catalytic intermediate. At higher [CO], signal intensity declined slightly. Attenuation of catalysis, methyl group transfer, and the NiFeC signal might reflect the same weak CO binding process. Three mutant alpha(2)beta(2) proteins designed to block the tunnel between the A- and C-clusters exhibited little/no activity with CO(2) as a substrate and no evidence of cooperative CO inhibition. This suggests that the tunnel was blocked by these mutations and that cooperative CO inhibition is related to tunnel operation. Numerous CO molecules might bind cooperatively to some region associated with the tunnel and institute a conformational change that abolishes the majority activity. Alternatively, crowding of CO in the tunnel may control flow through the tunnel and deliver CO to the A-cluster at the appropriate step of catalysis. Residual activity may involve CO from the solvent binding directly to the A-cluster.
Background:The Uba6 pathway and its components play an important role in a variety of biological processes. Results: The mechanism of how Uba6 activates two distinct substrates, ubiquitin and FAT10, was characterized. Conclusion: Uba6 was shown to use a similar mechanism for activating both substrates with a greater affinity for FAT10. Significance: Relative levels of ubiquitin and FAT10 could regulate the Uba6 pathway in cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.